COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03549741
Recruitment Status : Unknown
Verified May 2018 by Ahmed Abdeltawab Mhanny, Assiut University.
Recruitment status was:  Not yet recruiting
First Posted : June 8, 2018
Last Update Posted : June 8, 2018
Information provided by (Responsible Party):
Ahmed Abdeltawab Mhanny, Assiut University

Brief Summary:
Infertility refers to an inability to conceive after having regular unprotected sex. Infertility can also refer to the biological inability of an individual to contribute to conception, or to a female who cannot carry a pregnancy to full term. In many countries infertility refers to a couple that has failed to conceive after 12 months of regular sexual intercourse

Condition or disease Intervention/treatment Phase
Infertility Drug: Clomiphene Citrate 50mg Drug: Cabergoline Oral Tablet Drug: Placebo Oral Tablet Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility: Randomized Controlled Trial
Estimated Study Start Date : July 2018
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Infertility

Arm Intervention/treatment
Experimental: study group
will receive a dose of Clomiphene citrate 50 mg tablet , 1 tab twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package) first three months then Clomiphene citrate 50 mg tablet , 2 tabs twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package)
Drug: Clomiphene Citrate 50mg
oral tablets

Drug: Cabergoline Oral Tablet
oral tablets

Active Comparator: control group
will receive a dose of Clomiphene citrate and placebo tablets with same dose and duration
Drug: Clomiphene Citrate 50mg
oral tablets

Drug: Placebo Oral Tablet
oral tablets

Primary Outcome Measures :
  1. The number of mature follicles [ Time Frame: 14 days ]
    the follicles reach the size of 18 mm

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • unexplained infertility, Primary or secondary.
  • Absence of galactorrhoea.
  • Normal serum prolactin.
  • Normal hysterosalpingography.
  • Normal spermogram.

Exclusion Criteria:

  • Women on other line of treatment as aromatase inhibitors,gonadotrophins, or tamoxifen.
  • Known hypersensitivity for cabergoline or clomiphene citrate.
  • Other factors of infertility as tubal factor, uterine factor or male factor.
Layout table for additonal information
Responsible Party: Ahmed Abdeltawab Mhanny, Principal investigator, Assiut University Identifier: NCT03549741    
Other Study ID Numbers: CabCC
First Posted: June 8, 2018    Key Record Dates
Last Update Posted: June 8, 2018
Last Verified: May 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Genital Diseases, Male
Genital Diseases, Female
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents